ReviewMembranes2026
Advances and Challenges in Aerobic Granular Sludge Membrane Bioreactors for Treating Sulfamethoxazole in Wastewater.
Review in Membranes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Sulfamethoxazole (SMX) is one of the most frequently detected antibiotics in aquatic environments and is difficult to remove by conventional biological treatment because of its persistence, potential toxicity to microbial communities, and associated risk of antibiotic resistance selection. Aerobic granular sludge membrane bioreactors (AGMBRs), which combine the compact and stratified structure of aerobic granular sludge with membrane-based solid-liquid separation, have emerged as a promising platform for SMX-contaminated wastewater treatment because they provide high biomass retention, decoupled sludge retention time (SRT) and hydraulic retention time (HRT), and stable effluent quality. This review systematically summarizes recent advances in AGMBRs for SMX removal, with emphasis on how operating parameters (e.g., dissolved oxygen, hydraulic retention time, organic loading rate, C/N ratio, and sludge retention time) and membrane-related factors (e.g., membrane flux, aeration-induced shear, membrane type, and pore size) affect treatment performance and process stability. The main SMX attenuation pathways in AGMBRs are discussed from three perspectives: sorption and partitioning within granules and extracellular polymeric substances (EPSs), microbial biodegradation and co-metabolism, and membrane retention that prolongs effective contact time and shapes microbial ecology. Particular attention is given to the dual role of EPS and soluble microbial products (SMPs), which contribute to granule stability and SMX tolerance but also accelerate membrane fouling through cake-layer formation, pore blocking, and transmembrane pressure increase. Current challenges include incomplete understanding of transformation products, ARG- and MGE-related risks, long-term fouling-biodegradation interactions, and the lack of pilot-scale validation. Future research should therefore focus on mechanism clarification, integrated control of removal and fouling, energy-efficient operation, and scale-up of AGMBRs for practical antibiotic wastewater treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.